Pages that link to "Q35764582"
Jump to navigation
Jump to search
The following pages link to Rational combination treatment with histone deacetylase inhibitors and immunomodulatory drugs in multiple myeloma (Q35764582):
Displaying 29 items.
- Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial (Q33167710) (← links)
- A phase IIb trial of vorinostat in combination with lenalidomide and dexamethasone in patients with multiple myeloma refractory to previous lenalidomide-containing regimens (Q33436890) (← links)
- Developing selective histone deacetylases (HDACs) inhibitors through ebselen and analogs (Q33649853) (← links)
- Enhancement of pomalidomide anti-tumor response with ACY-241, a selective HDAC6 inhibitor (Q36298507) (← links)
- HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide (Q36544516) (← links)
- Effects of Anticancer Drugs on Chromosome Instability and New Clinical Implications for Tumor-Suppressing Therapies (Q36787517) (← links)
- Mechanisms and Clinical Applications of Genome Instability in Multiple Myeloma. (Q38637046) (← links)
- Panobinostat for the management of multiple myeloma (Q38806260) (← links)
- Histone deacetylase inhibitors in multiple myeloma: from bench to bedside (Q38813504) (← links)
- Treatment of MM: Upcoming Novel Therapies (Q38815402) (← links)
- How do tumor cells respond to HDAC inhibition? (Q38817005) (← links)
- Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma (Q39040044) (← links)
- Novel Proteasome Inhibitors and Histone Deacetylase Inhibitors: Progress in Myeloma Therapeutics (Q39234159) (← links)
- Epigenetic regulatory mutations and epigenetic therapy for multiple myeloma (Q39261435) (← links)
- Role of epigenetics-microRNA axis in drug resistance of multiple myeloma (Q39379624) (← links)
- Strategy for enhancing the therapeutic efficacy of histone deacetylase inhibitor dacinostat: the novel paradigm to tackle monotonous cancer chemoresistance (Q41203569) (← links)
- Promising therapies in multiple myeloma (Q42581682) (← links)
- HDAC3 regulates DNMT1 expression in multiple myeloma: therapeutic implications (Q43246885) (← links)
- MUC1-C is a target in lenalidomide resistant multiple myeloma (Q46345708) (← links)
- Immunomodulation by Entinostat in Renal Cell Carcinoma Patients Receiving High-Dose Interleukin 2: A Multicenter, Single-Arm, Phase I/II Trial (NCI-CTEP#7870). (Q46444003) (← links)
- Crucial role of HO-1/IRF4-dependent apoptosis induced by panobinostat and lenalidomide in multiple myeloma (Q47216231) (← links)
- Emerging small molecule approaches to enhance the antimyeloma benefit of proteasome inhibitors (Q50026815) (← links)
- Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137). (Q51188342) (← links)
- The Therapeutic Strategy of HDAC6 Inhibitors in Lymphoproliferative Disease (Q58792448) (← links)
- A Systematic Review of miR-29 in Cancer (Q61811185) (← links)
- Immunotherapeutics in Multiple Myeloma: How Can Translational Mouse Models Help? (Q64060100) (← links)
- Phthalimide Derivative Shows Anti-angiogenic Activity in a 3D Microfluidic Model and No Teratogenicity in Zebrafish Embryos (Q64105379) (← links)
- HDAC Inhibitors Exert Anti-Myeloma Effects through Multiple Modes of Action. (Q64928553) (← links)
- Cladribine in combination with entinostat synergistically elicits anti-proliferative/anti-survival effects on multiple myeloma cells (Q89403508) (← links)